Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,213 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Neuroendocrine Tumor Clear all
Completed Phase 2 Interventional Results available

A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma

NCT01153763
View directory record Official record
Conditions
Melanoma
Interventions
GSK2118436
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

NCT02031536
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
everolimus, placebo
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085
View directory record Official record
Conditions
BRAF or NRAS Mutant Metastatic Melanoma
Interventions
MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
10
States / cities
Fayetteville, Arkansas • Tampa, Florida • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

NCT01204476
View directory record Official record
Conditions
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions
Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 1 Interventional

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

NCT05859074
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Angiosarcoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor
Interventions
MQ719, Pembrolizumab
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

NCT02500576
View directory record Official record
Conditions
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Pembrolizumab, Quality-of-Life Assessment, Therapeutic Tumor Infiltrating Lymphocytes
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 1 Interventional

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor
Interventions
PLN-101095, Pembrolizumab
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
12
States / cities
New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

NCT00701987
View directory record Official record
Conditions
Melanoma
Interventions
ALS-357
Drug
Lead sponsor
Advanced Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 17, 2026, 5:16 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

NCT05180799
View directory record Official record
Conditions
NSCLC, Melanoma
Interventions
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
Biological · Drug
Lead sponsor
BioAtla, Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Dyer, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

NCT00026221
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
Recombinant Interferon Alfa, Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

NCT01239134
View directory record Official record
Conditions
Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Interventions
TRX518
Biological
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

NCT06546553
View directory record Official record
Conditions
Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
Drug · Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Trial of pIL-12/MK-3475 in Metastatic Melanoma

NCT02493361
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, pIL-12
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

NCT01152788
View directory record Official record
Conditions
Melanoma
Interventions
rIL-21, Dacarbazine
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

NCT00970996
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide, Abraxane, Cisplatin, Interleukin-2, Interferon alpha 2b
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Phase II Trial of Allovectin-7® for Metastatic Melanoma

NCT00044356
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer
Interventions
Allovectin-7®
Genetic
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bakersfield, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

NCT01495988
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
Vemurafenib, Bevacizumab, Cobimetinib
Drug
Lead sponsor
Melanoma Research Foundation Breakthrough Consortium
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

NCT05262556
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Neuroendocrine Carcinoma, Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
Interventions
NP-101 (TQ Formula), Nivolumab (3mg/kg), Ipilimumab (1mg/kg)
Drug
Lead sponsor
Amr Mohamed MD
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

NCT02073123
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Melanoma, Stage IV Melanoma
Interventions
Indoximod, Ipilimumab, Nivolumab, Pembrolizumab
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Augusta, Georgia • Iowa City, Iowa • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Not listed Phase 2 Interventional

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

NCT05077280
View directory record Official record
Conditions
Uveal Melanoma
Interventions
stereotactic body radiotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00085423
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, sargramostim, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Sep 17, 2026, 5:16 AM EDT